Upregulation of connexin 30 in intestinal phenotype gastric cancer and its reduction during tumor progression

Pathobiology

Volumn 77, Issue 5, 2010, Pages 241-248

  Sentani, Kazuhiro ^a   Oue, Naohide ^a   Sakamoto, Naoya ^a   Anami, Katsuhiro ^a   Naito, Yutaka ^a   Aoyagi, Kazuhiko ^b   Sasaki, Hiroki ^b   Yasui, Wataru ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Connexin 30; Gastric cancer; Intestinal phenotype; Microarray

Indexed keywords

COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CONNEXIN 30; MUCIN 2; MUCIN 5AC; MUCIN 6; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CONTROLLED STUDY; FEMALE; GENETIC IDENTIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE CANCER; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; CONNEXINS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MUCIN 5AC; MUCIN-2; MUCIN-6; NEOPLASM STAGING; NEPRILYSIN; PHENOTYPE; PROTEIN ARRAY ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 78649844934     PISSN: 10152008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000314966     Document Type: Article

References (58)

1. Ohgaki H, Matsukura N: Stomach cancer; in Stewart BW, Kleihues P (eds): World Cancer Report. Lyon, IARC Press, 2003, p 197.
2. Yasui W, Yokozaki H, Fujimoto J, Naka K, Kuniyasu H, Tahara E: Genetic and epigenetic alterations in multistep carcinogenesis of the stomach. J Gastroenterol 2000;35:111-115.
3. Ushijima T, Sasako M: Focus on gastric cancer. Cancer Cell 2004;5:121-125.
4. Yasui W, Oue N, Ito R, Kuraoka K, Nakayama H: Search for new biomarkers of gastric cancer through serial analysis of gene expression and its clinical implications. Cancer Sci 2004;95:385-392.
5. Lockhart DJ, Dong H, Byrne MC, et al: Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol 1996;14:1675-1680.
6. Velculescu VE, Zhang L, Vogelstein B, Kinzler KW: Serial analysis of gene expression. Science 1995;270:484-487.
7. Lauren P: The two histological main types of gastric carcinoma: diffuse and so-called intestinaltype carcinoma. An attempt at a histoclinical classification. Acta Pathol Microbiol Scand 1965;64:31-49.
8. Nakamura K, Sugano H, Takagi K: Carcinoma of the stomach in incipient phase: its histogenesis and histological appearances. Gann 1968;59:251-258.
9. Saito K, Shimoda T: The histogenesis and early invasion of gastric cancer. Acta Pathol Jpn 1986;36:1307-1318.
10. Tahara E: Genetic alterations in human gastrointestinal cancers: the application to molecular diagnosis. Cancer 1995;75:1410-1417.
11. Tatematsu M, Ichinose M, Miki K, Hasegawa R, Kato T, Ito N: Gastric and intestinal phenotypic expression of human stomach cancers as revealed by pepsinogen immunohistochemistry and mucin histochemistry. Acta Pathol Jpn 1990;40:494-504.
12. Yoshikawa A, Inada Ki K, Yamachika T, Shimizu N, Kaminishi M, Tatematsu M: Phenotypic shift in human differentiated gastric cancers from gastric to intestinal epithelial cell type during disease progression. Gastric Cancer 1998;1:134-141.
13. Tajima Y, Yamazaki K, Nishino N, et al: Gastric and intestinal phenotypic marker expression in gastric carcinomas and recurrence pattern after surgery - immunohistochemical analysis of 213 lesions. Br J Cancer 2004;91:1342-1348.
14. Saito A, Shimoda T, Nakanishi Y, Ochiai A, Toda G: Histologic heterogeneity and mucin phenotypic expression in early gastric cancer. Pathol Int 2001;51:165-171.
15. Kabashima A, Yao T, Sugimachi K, Tsuneyoshi M: Relationship between biologic behavior and phenotypic expression in intramucosal gastric carcinomas. Hum Pathol 2002;33:80-86.
16. Shibata N, Watari J, Fujiya M, Tanno S, Saitoh Y, Kohgo Y: Cell kinetics and genetic instabilities in differentiated type early gastric cancers with different mucin phenotype. Hum Pathol 2003;34:32-40.
17. Tsukashita S, Kushima R, Bamba M, Sugihara H, Hattori T: MUC gene expression and histogenesis of adenocarcinoma of the stomach. Int J Cancer 2001;94:166-170.
18. Wakatsuki K, Yamada Y, Narikiyo M, et al: Clinicopathological and prognostic significance of mucin phenotype in gastric cancer. J Surg Oncol 2008;98:124-129.
19. Yuasa Y: Control of gut differentiation and intestinal-type gastric carcinogenesis. Nat Rev Cancer 2003;3:592-600.
20. Mizoshita T, Tsukamoto T, Nakanishi H, et al: Expression of Cdx2 and the phenotype of advanced gastric cancers: relationship with prognosis. J Cancer Res Clin Oncol 2003;129:727-734.
21. Tsukamoto T, Inada K, Tanaka H, et al: Down-regulation of a gastric transcription factor, Sox2, and ectopic expression of intestinal homeobox genes, Cdx1 and Cdx2: inverse correlation during progression from gastric/intestinal- mixed to complete intestinal metaplasia. J Cancer Res Clin Oncol 2004;130:135-145.
22. Evans WH, Martin PE: Gap junctions: structure and function (Review). Mol Membr Biol 2002;19:121-136.
23. Kumar NM, Gilula NB: The gap junction communication channel. Cell 1996;84:381-388.
24. Goodenough DA, Goliger JA, Paul DL: Connexins, connexons, and intercellular communication. Annu Rev Biochem 1996;65:475-502.
25. Janssen-Timmen U, Traub O, Dermietzel R, Rabes HM, Willecke K: Reduced number of gap junctions in rat hepatocarcinomas detected by monoclonal antibody. Carcinogenesis 1986;7:1475-1482.
26. Mesnil M: Connexins and cancer. Biol Cell 2002;94:493-500.
27. Muramatsu A, Iwai M, Morikawa T, et al: Influence of transfection with connexin 26 gene on malignant potential of human hepatoma cells. Carcinogenesis 2002;23:351-358.
28. Tanaka M, Grossman HB: Connexin 26 gene therapy of human bladder cancer: induction of growth suppression, apoptosis, and synergy with Cisplatin. Hum Gene Ther 2001;12:2225-2236.
29. Villaret DB, Wang T, Dillon D, et al: Identification of genes overexpressed in head and neck squamous cell carcinoma using a combination of complementary DNA subtraction and microarray analysis. Laryngoscope 2000;110:374-381. (Pubitemid 30143678)
30. Kanczuga-Koda L, Sulkowski S, Koda M, Sulkowska M: Alterations in connexin26 expression during colorectal carcinogenesis. Oncology 2005;68:217-222.
31. Tate AW, Lung T, Radhakrishnan A, Lim SD, Lin X, Edlund M: Changes in gap junctional connexin isoforms during prostate cancer progression. Prostate 2006;66:19-31.
32. Kyo N, Yamamoto H, Takeda Y, et al: Overexpression of connexin 26 in carcinoma of the pancreas. Oncol Rep 2008;19:627-631.
33. Jamieson S, Going JJ, D'Arcy R, George WD: Expression of gap junction proteins connexin 26. and connexin 43 in normal human breast and in breast tumours. J Pathol 1998;184:37-43.
34. Kanczuga-Koda L, Sulkowski S, Lenczewski A, et al: Increased expression of connexins 26. and 43 in lymph node metastases of breast cancer. J Clin Pathol 2006;59:429-433.
35. Dahl E, Manthey D, Chen Y, et al: Molecular cloning and functional expression of mouse connexin-30, a gap junction gene highly expressed in adult brain and skin. J Biol Chem 1996;271:17903-17910.
36. Lautermann J, Frank HG, Jahnke K, Traub O, Winterhager E: Developmental expression patterns of connexin26 and-30 in the rat cochlea. Dev Genet 1999;25:306-311.
37. Nagy JI, Patel D, Ochalski PA, Stelmack GL: Connexin30 in rodent, cat and human brain: selective expression in gray matter astrocytes, co-localization with connexin43 at gap junctions and late developmental appearance. Neuroscience 1999;88:447-468.
38. Grifa A, Wagner CA, D'Ambrosio L, et al: Mutations in GJB6 cause nonsyndromic autosomal dominant deafness at DFNA3 locus. Nat Genet 1999;23:16-18.
39. Del Castillo I, Villamar M, Moreno-Pelayo MA, et al: A deletion involving the connexin 30. gene in nonsyndromic hearing impairment. N Engl J Med 2002;346:243-249.
40. Smith FJ, Morley SM, McLean WH: A novel connexin 30 mutation in Clouston syndrome. J Invest Dermatol 2002;118:530-532.
41. Ozawa H, Matsunaga T, Kamiya K, et al: Decreased expression of connexin-30 and aberrant expression of connexin-26 in human head and neck cancer. Anticancer Res 2007;27:2189-2195.
42. Aasen T, Graham SV, Edward M, Hodgins MB: Reduced expression of multiple gap junction proteins is a feature of cervical dysplasia. Mol Cancer 2005;4:31.
43. Haass NK, Wladykowski E, Kief S, Moll I, Brandner JM: Differential induction of connexins 26. and 30 in skin tumors and their adjacent epidermis. J Histochem Cytochem 2006;54:171-182.
44. Japanese Gastric Cancer Association: Japanese Classification of Gastric Carcinoma, ed 13. Tokyo, Kanehara, 1995.
45. Sobin LH, Wittekind CH (eds): TNM Classification of Malignant Tumors, ed 6. New York, Wiley, 2002, pp 65-68.
46. Gibson UE, Heid CA, Williams PM: A novel method for real time quantitative RT-PCR. Genome Res 1996;6:995-1001.
47. Kondo T, Oue N, Yoshida K, et al: Expression of POT1 is associated with tumor stage and telomere length in gastric carcinoma. Cancer Res 2004;64:523-529.
48. Oue N, Mitani Y, Aung PP, et al: Expression and localization of Reg IV in human neoplastic and non-neoplastic tissues: Reg IV expression is associated with intestinal and neuroendocrine differentiation in gastric adenocarcinoma. J Pathol 2005;207:185-198.
49. Essenfelder GM, Bruzzone R, Lamartine J, et al: Connexin30 mutations responsible for hidrotic ectodermal dysplasia cause abnormal hemichannel activity. Hum Mol Genet 2004;13:1703-1714.
50. Zhu D, Kidder GM, Caveney S, Naus CC: Growth retardation in glioma cells cocultured with cells overexpressing a gap junction protein. Proc Natl Acad Sci USA 1992;89:10218-10221.
51. Goldberg GS, Bechberger JF, Tajima Y, et al: Connexin43 suppresses MFG-E8 while inducing contact growth inhibition of glioma cells. Cancer Res 2000;60:6018-6026.
52. Seul KH, Kang KY, Lee KS, Kim SH, Beyer EC: Adenoviral delivery of human connexin37 induces endothelial cell death through apoptosis. Biochem Biophys Res Commun 2004;319:1144-1151.
53. Moorby C, Patel M: Dual functions for connexins: Cx43 regulates growth independently of gap junction formation. Exp Cell Res 2001;271:238-248.
54. Princen F, Robe P, Gros D, et al: Rat gap junction connexin-30 inhibits proliferation of glioma cell lines. Carcinogenesis 2001;22:507-513.
55. Mennecier G, Derangeon M, Coronas V, Herve JC, Mesnil M: Aberrant expression and localization of connexin43 and connexin30 in a rat glioma cell line. Mol Carcinog 2008;47:391-401.
56. Saunders MM, Seraj MJ, Li Z, et al: Breast cancer metastatic potential correlates with a breakdown in homospecific and heterospecific gap junctional intercellular communication. Cancer Res 2001;61:1765-1767.
57. Yum SW, Zhang J, Valiunas V, et al: Human connexin26 and connexin30 form functional heteromeric and heterotypic channels. Am J Physiol Cell Physiol 2007;293:1032-1048.
58. Yamamoto T, Kojima T, Murata M, et al: IL-1beta regulates expression of Cx32, occludin, and claudin-2 of rat hepatocytes via distinct signal transduction pathways. Exp Cell Res 2004;299:427-441.